MedTrace Logo

A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers

NCT03920579 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-04-19

No results posted yet for this study

Summary

a study to investigate the pharmacokinetic characteristics and safety/tolerability according to formulations of CKD-386 in healthy male volunteers

Conditions

Interventions

DRUG

CKD-386 formulation 1

A single oral dose of 1 tablet under fasting conditions for each period

DRUG

CKD-386 formulation 2

A single oral dose of 1 tablet under fasting conditions for each period

DRUG

D326, D337 and D013

A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Dongseong Shin, M.D, Ph.D · Clinical Trials Center, Gil Medical Center, Incheon, Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2019-05-31
Completion
2019-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03920579 on ClinicalTrials.gov